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This study was conducted to evaluate the possible clinical and bacteriologic features
associated with 30-day mortality from Acinetobacter baumannii (A. baumannii)
bloodstream infections (BSIs). We conducted a prospective, multicenter, observational
study of 181 entire episodes of A. baumannii BSI from six general hospitals between
May 2016 and April 2017 in South Korea. Cox proportional-hazards regression model
was used to estimate risks of the primary endpoint, i.e., all-cause mortality within 30 days
from the initial blood culture. Most (84.5%) of the A. baumannii blood isolates belonged to
the international clonal lineage II (ICLII) and 89.5% of the isolates were either multidrug- or
extensively-drug resistant. We identified three risk factors including the old age of patient
{hazard ratio, 1.033; [95% Confidential Interval (CI), 1.010–1.056]}, the sequential organ
failure assessment score [1.133 (1.041–1.233)], and causative A. baumannii sequence
type (ST) 191 belonging to ICLII [1.918 (1.073–3.430)], and three protective factors
including causative A. baumannii ST451 belonging to ICLII [0.228 (0.078–0.672)], platelet
count [0.996 (0.993–0.999)], and definitive therapy within 72 h [0.255 (0.125–0.519)].
Differing 30-day mortality rate in the dominant ICLII was observed by ST, which was
much high in ST191 and low in ST451 and it was likely associated with the molecular
traits, rather than the drug resistance.
Keywords: Acinetobacter baumannii, bloodstream infection, international clonal lineage II, ST191, ST451
Yoon et al. Acinetobacter baumannii Bloodstream Infection
INTRODUCTION
Acinetobacter baumannii is dominant in clinical settings
primarily targeting immunocompromised patients in intensive
care units (ICUs) and has the potential to cause healthcare-
associated infections (1). Infections caused by A. baumannii have
repeatedly been reported to have grave clinical outcomes (2, 3).
A. baumannii has an epidemic potential of emerging diseases
because of its ability to persist in hospital environments by
resisting desiccation and disinfectants (1). A propensity toward
rapid acquisition of foreign DNA, including antimicrobial
resistance determinants and virulence determinants, also
contributes to its effective dissemination (4).
Previous studies have demonstrated that A. baumannii
infections are accompanied by serious morbidity and mortality
associated with a high sequential organ failure assessment
(SOFA) score (5), comorbidities (6), immunosuppression (3),
and antimicrobial treatment failure, mainly due to the multidrug
resistance (MDR) of the causative A. baumannii (5, 7, 8). The
rates of resistance to the major anti-Acinetobacter agents are
increasing (9). In particular in South Korea, predominance of
the multidrug-resistant international clonal lineage II (ICLII) in
hospital settings is of great concern (10–12).
This study was performed to evaluate the possible clinical
and bacteriologic features associated with 30-day mortality from
A. baumannii bloodstream infection (BSI) for the entire 1-year
incidence of A. baumannii BSI cases of multiple general hospitals
in South Korea.
METHODS
Study Design
A prospective, multicenter, observational study was designed
to monitor the entire A. baumannii BSI episodes between
May 2016 and April 2017 occurring in six general hospitals
with 715–1,050 beds participating in a national surveillance
study of antimicrobial resistance in South Korea (13). Local
ethics committee approvals were expedited or waived at each
participating hospital since the study had a purely observational
nature. The A. baumannii BSI cases were detected through
reviewing daily blood culture results. One authorized investigator
at each hospital reviewed patients’ medical records, all of the
raw data were recorded in a pre-formatted spreadsheet, and the
datasheet was submitted via email to an analysis center without
monitoring. Prognoses of patients were followed for at least
30 days and the cases of transfer and hospital discharge were
recorded as they were. The Charlson comorbidity index (14)
and the SOFA score (15) were calculated in the analysis center
using the collected raw data for the day of initial blood culture.
For the sequential isolation of A. baumannii from one patient,
the first isolate was used for analyses and the ensuing isolates
were discarded. Among a total of 67,803 patients subjected to
blood culture, A. baumannii isolates were recovered from blood
specimens of 188 patients, and following the elimination of 7
episodes of death on the day of the initial blood culture, 181 cases
were included in the analysis. The microbiological assessment
was carried out in the analysis center.
Definitions
Laboratory-confirmed A. baumannii BSI was defined as an
A. baumannii-positive blood culture from one or more blood
specimens (16). Hospital-originated (HO) infection was specified
by ≥2 calendar days of hospitalization at the day of initial
blood culture, including the time spent at a previous health
care facility before transfer. The 30-day mortality was defined
as all-cause mortality within 30 days from the initial blood
culture. Non-susceptibility (NS) to a drug class was defined as
NS to at least one drug in a class and resistance phenotypes
were categorized following Magiorakos et al. (17): MDR (NS
to three or more drug classes), extensively drug resistance
(XDR, NS to at least one agent in all but one or two
drug classes), and pan-drug resistance (NS to at least one
agent in all drug classes). An empirical antimicrobial therapy
was defined as an initial antimicrobial treatment before the
susceptibility testing results for the causative pathogen. A
definitive antimicrobial therapy was defined as prescribing
a revised antimicrobial regimen based on the antimicrobial
susceptibility testing results and, if the revised regimen was
administered after 72 h, it was deemed to be a delayed
definitive therapy. Adequate antimicrobial therapy must include
at least one antimicrobial agent active in vitro and both
the dosage and route of administration should meet current
medical standards.
Microbiological Assessment
Bacterial species were initially identified by matrix assisted
laser desorption/ionization time-of-flight mass spectrometry
using a Bruker BiotyperTM system (Billerica, MA, USA) and
the detailed species of Acinetobacter spp. were confirmed
by PCR and sequencing the rpoB gene. For A. baumannii,
multilocus sequence typing was followed through the
Oxford scheme (18). Antimicrobial susceptibility was tested
following the Clinical and Laboratory Standards Institute
(CLSI) guidelines (19). Antimicrobial susceptibilities to
13 anti-Acinetobacter agents belonging to seven drug
classes were tested by the disk diffusion method. For
carbapenem-resistant isolates, the blaOXA−23 gene and the
ISAba1-blaOXA−51−like were identified by PCR and direct
sequencing (20). Colistin MICs were determined by the
broth microdilution method (21). Twenty-six virulence
genes associated with eight virulence characteristics (22)
were investigated by real-time PCR using gene-specific
primers (23) and a KAPA SYBR Fast quantitative PCR
master mix (Kapa biosystems, Inc., Wilmington, MA, USA).
The resistance islands AbaR and AbGRI1 were specified
by PCR using a set of primers, comMtr3_145-126F (5′-
CAAGCGGTTGGCGTAAGACT-3′) and reverse primers
tniB_546-525R (5′-CAAGTACATGCTCTGCAAGATG-
3′) only for the full tniB gene and tniB_37-16R (5′-
CAGACTCAATTCATTGCTGAGG-3′) for both the full
and the truncated tniB genes.
Statistical Analysis
Statistical analyses were performed in SPSS statistics (version
23, IBM Corp., Armonk, NY, USA). Data are expressed as
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the mean ± standard deviation if no special description is
indicated. Categorical variables were compared by Pearson’s
X2 test, and continuous variables were compared by an
independent two sample t-test. Associations between 30-day
mortality and risk factors were evaluated using univariable
and multivariable Cox proportional hazard regression
models. The proportional hazards assumption was evaluated
by including an interaction term between variables, and
variables were natural-log transformed by follow-up time
and by log-minus-log survival plots. For multivariable
analyses, variables with a P value <0.1 in univariable
analyses were considered to include any possible variables.
Multicollinearity between variables was diagnosed by calculating
the variance inflation factors, and a multivariable analysis
was conducted by the backward stepwise method. All tests of
significance were two-tailed; P values <0.05 were considered to
be significant.
RESULTS
Characteristics of Enrolled Patients
A total of 181 laboratory-confirmed A. baumannii BSI cases were
enrolled from the six participating hospitals and the number of
cases was ranged from 22 to 52 by hospital (Figure 1). Among
patients with A. baumannii BSIs, the sex ratio of male vs. female
was 115:66, and their mean age was 67.7 ± 14.3 years (Table 1).
The mean Charlson comorbidity index score was 4.1 ± 2.2.
Solid tumors (26.5%, 48/181), diabetes mellitus (23.2%, n = 42),
cerebrovascular diseases (18.2%, n= 33), kidney diseases (13.8%,
n = 25), and chronic pulmonary diseases (6.6%, n = 12) were
the five most observed underlying diseases and dementia (n =
9) and chronic liver diseases (n = 7) were followed. Of the
total, 88.4% (n = 160) of cases were HO infections, 95.0% (n
= 172) were inpatients, and 68.0% of those (117/172) stayed
in ICUs. The SOFA score had a mean value of 5.9 ± 3.5.
Secondary BSIs were identified in 44.2% (80/181) of cases, and
the majority (86.3%, 69/80) were originated from a pulmonary
tract infection.
The BSI-Causative A. baumannii Isolates
Sequence Types
The majority of the A. baumannii blood isolates belonged to
ICLII (84.5%, 153/181) and the ICLII mostly comprised sequence
type (ST) 191 (allele numbers of gltA-gyrB-gdhB-recA-cpn60-gpi-
rpoD, 1-3-3-2-2-94-3; 47.7%, 73/153), ST784 (1-3-3-2-2-107-3;
20.3%, n = 31), and ST451 (1-3-3-2-2-142-3; 19.0%, n = 29).
The 30-day mortality rate of patients with A. baumannii ICLII
BSIs was 1.83-fold higher than that with A. baumannii BSIs by
non-ICLII strains (45.8 vs. 25.0%); and among the ICLII BSIs,
the 30-day mortality rate with ST191 BSIs was the highest and,
the lowest for ST451 BSIs (60.3 vs. 17.2%).
Antimicrobial Resistance
Majority of the A. baumannii blood isolates (89.5%, 162/181)
were either MDR or XDR, and the proportion was markedly
greater in A. baumannii ICLII (98.7%, 151/153; 18 MDR and 133
XDR) than in non-ICLII (39.3%, 11/28; 5 MDR, and 6 XDR).
All of the tested isolates were susceptible to colistin, and no pan-
drug resistant isolate was observed. All but one carbapenem-NS
A. baumannii harbored the blaOXA−23 gene (99.4%, 159/160)
and the remaining one carried an insertion sequence ISAba1
upstream from the blaOXA−51−like gene. Two thirds and one-
quarter of A. baumannii possessed AbGRI1 (63.0%, 114/181) and
AbaR (26.5%, 48/181), respectively.
Virulence Factors
Factors for adhesion and membrane integrity, biofilm formation,
carbohydrate metabolism, quorum sensing, and siderophore
FIGURE 1 | Participating sentinel hospitals and collected Acinetobacter baumannii blood isolates. Locations of the hospitals (in gray) and covering parts (in gray
patterns) are indicated in a map of the South Korean peninsula, respectively, and the associated table represent information regarding blood isolates from each
hospital including demographic information from 2016. HO, hospital-origin; ICLII, international clonal lineage II; ST, sequence type.
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TABLE 1 | Thirty day mortality-associated factors for patients with an Acinetobacter baumannii BSI.
Variables Total* Survival 30-day death† P‡ Univariate model
n = 181 n = 104 n = 77 HR [95%CI]§ P
Demographic information
Male 115 (63.5%) 67 (64.4%) 48 (62.3%) 0.876 0.883 [0.557–1.400] 0.596
Age 67.7 ± 14.3 64.5 ± 15.5 72.1 ± 11.1 <0.001 1.033 [1.014–1.054] <0.001
Inpatients 172 (95%) 98 (94.2%) 74 (96.1%) 0.735 1.355 [0.427–4.298] 0.606
Hospital origin 160 (88.4%) 87 (83.7%) 73 (94.8%) 0.033 2.808 [1.026–7.685] 0.044
Intensive care unit 117 (64.6%) 63 (60.6%) 54 (70.1%) 0.210 1.342 [0.824–2.187] 0.238
Underlying disease¶
Charlson index 4.1 ± 2.2 3.9 ± 2.2 4.4 ± 2.2 0.108 1.086 [0.981–1.202] 0.112
Solid tumor 48 (26.5%) 27 (26.0%) 21 (27.3%) 0.866 1.183 [1.109–1.261] <0.001
Diabetes mellitus 42 (23.2%) 28 (26.9%) 14 (18.2%) 0.213 0.049 [0.000–7177] 0.620
Cerebrovascular disease 33 (18.2%) 23 (22.1%) 10 (13.0%) 0.125 0.597 [0.307–1.161] 0.129
Kidney disease 25 (13.8%) 15 (14.4%) 10 (13.0%) 0.831 1.043 [0.631–1.722] 0.870
Chronic pulmonary diseases 12 (6.6%) 7 (6.7%) 5 (6.5%) >0.999 6.176 [0.840–45.40] 0.074
Chronic liver diseases 7 (3.9%) 2 (1.9%) 5 (6.5%) 0.137 2.182 [0.878–5.420] 0.093
Dementia 9 (5.0%) 5 (4.8%) 4 (5.2%) >0.999 1.069 [0.432–2.649] 0.885
Other# 5 (2.8%) 2 (1.9%) 3 (3.9%) 0.652 1.019 [0.372–2.787] 0.971
Severity variables
SOFA score 5.9 ± 3.5 4.8 ± 3.2 7.4 ± 3.5 <0.001 1.183 [1.109–1.261] <0.001
Lab data
WBC 11.5 ± 7.8 12.2 ± 6.9 10.6 ± 8.8 0.185 0.967 [0.934–1.000] 0.052
Hb 10.4 ± 7.8 10.9 ± 10.4 9.6 ± 1.6 0.262 0.910 [0.788–1.051] 0.201
Platelet 169.7 ±
132.1
206.9 ±
138.3
119.5 ± 104.8 <0.001 0.994 [0.991–0.997] <0.001
Origin of infection¶
Pulmonary tract 69 (38.1%) 36 (34.6%) 33 (42.9%) 0.281 1.259 [0.801–1.978] 0.317
Wound 7 (3.9%) 5 (4.8%) 2 (2.6%) 0.700 0.653 [0.160–2.662] 0.553
Urinary tract 4 (2.2%) 4 (3.8%) 0 (0%) 0.138 0.048 [0.000–18.92] 0.319
Causative pathogen
Polymicrobial infection 44 (24.3%) 30 (28.8%) 14 (18.2%) 0.116 0.636 [0.356–1.135] 0.125
ICLII†† 153 (84.5%) 83 (79.8%) 70 (90.9%) 0.060 2.083 [0.958–4.533] 0.064
ST191 (1-3-3-2-2-94-3) 73 (40.3%) 29 (27.9%) 44 (57.1%) <0.001 2.630 [1.671–4.139] <0.001
ST784 (1-3-3-2-2-107-3) 31 (17.1%) 17 (16.3%) 14 (18.2%) 0.842 0.983 [0.551–1.755] 0.954
ST451 (1-3-3-2-2-142-3) 29 (16.0%) 24 (23.1%) 5 (6.5%) 0.004 0.293 [0.118–0.727] 0.008
Virulence factors
Bacterial lipocalin, Blc 145 (80.1%) 79 (76.0%) 66 (85.7%) 0.132 1.540 [0.813–2.916] 0.185
Pro-apoptotic porin, PorB 146 (80.7%) 79 (76.0%) 67 (87.0%) 0.086 1.839 [0.946–3.575] 0.073
Small protein A, SmpA 177 (97.8%) 101 (97.1%) 76 (98.7%) 0.638 1.773 [0.247–12.75] 0.569
Pili, Csu 73 (40.3%) 45 (43.3%) 28 (36.4%) 0.363 0.781 [0.491–1.243] 0.297
PNAG, Pga 173 (95.6%) 96 (92.3%) 77 (100%) 0.022 22.02 [0.307–1579] 0.156
Polysaccharide exporter, EpsA 9 (5.0%) 7 (6.7%) 2 (2.6%) 0.305 0.425 [0.104–1.730] 0.232
Capsule protein, MviM 7 (3.9%) 4 (3.8%) 3 (3.9%) >0.999 1.047 [0.330–3.322] 0.938
Lipopolysaccharide, VipA 16 (8.8%) 9 (8.7%) 7 (9.1%) >0.999 1.021 [0.469–2.220] 0.959
Lipopolysaccharide, Wzx 48 (26.5%) 26 (25%) 22 (28.6%) 0.613 1.144 [0.698–1.875] 0.595
Glyconokinase, GntK 179 (98.9%) 102 (98.1%) 77 (100%) 0.508 20.54 [0.004–93770] 0.482
Quorum Sensing, LuxR 159 (87.8%) 91 (87.5%) 68 (88.3%) >0.999 1.000 [0.499–2.004] 0.999
Motility and secretion, PilA 18 (9.9%) 12 (11.5%) 6 (7.8%) 0.460 0.723 [0.314–1.664] 0.446
Siderophore, BasD 179 (98.9%) 102 (98.1%) 77 (100%) 0.508 20.54 [0.004–93770] 0.482
Antimicrobial resistance
Penicillins NS 157 (86.7%) 82 (78.8%) 75 (97.4%) <0.001 7.352 [1.804–29.96] 0.005
3-, 4- gen. cephalosporins NS 162 (89.5%) 85 (81.7%) 77 (100%) <0.001 25.33 [1.463–438.6] 0.026
(Continued)
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TABLE 1 | Continued
Variables Total* Survival 30-day death† P‡ Univariate model
n = 181 n = 104 n = 77 HR [95%CI]§ P
Carbapenems NS 160 (88.4%) 84 (80.8%) 76 (98.7%) <0.001 13.15 [1.828–94.63] 0.010
Aminoglycosides NS 141 (77.9%) 76 (73.1%) 65 (84.4%) 0.073 1.515 [0.818–2.805] 0.187
Fluoroquinolones NS 162 (89.5%) 85 (81.7%) 77 (100%) <0.001 25.33 [1.463–438.6] 0.026
Tetracyclines NS 13 (7.2%) 11 (10.6%) 2 (2.6%) 0.045 0.284 [0.070–1.156] 0.079
Drug susceptible 18 (9.9%) 18 (17.3%) 0 (0%) <0.001 0.040 [0.002–0.743] 0.031
MDR/XDR 162 (89.5%) 85 (81.7%) 77 (100%) <0.001 25.33 [1.463–438.6] 0.026
Treatment
Adequate empirical therapy 49 (27.1%) 30 (28.8%) 19 (24.7%) 0.613 0.744 [0.443–1.249] 0.263
Definitive therapy within 72 h 49 (27.1%) 39 (37.5%) 10 (13.0%) <0.001 0.246 [0.124–0.488] <0.001
*The percentage was calculated from the total number of AB-BSI.
†
All-cause mortality within 30 days from the initial blood culture.
‡P value is either from Pearson’s X2 test for categorical data or from the t-test for continuous data. Bonferroni corrected significance level from 32 hypotheses was considered to be P
< 0.0016, and the significant P values are indicated in bold.
§Cox proportional hazards regression model was applied to calculate the hazard ratio (HR) and the 95% confidence interval (CI).
¶Underlying disease and primary site of infection could be multiple by patient.
#Ulcer (n = 2), connective tissue disease (n = 2), congestive cardiac insufficiency (n = 2), and leukemia (n = 2) are included.
††
Multilocus sequence typing profiles are indicated with the combination of alleles (gltA-gyrB-gdhB-recA-cpn60-gpi-rpoD).
SD, standard deviation; ICLII, the international clonal lineage II.
were detected in A. baumannii blood isolates (Table 1). The
acinetobactin-associated basD (98.9%, 179/181), the glycokinase
gntK (98.9%, n = 179), the adhesion-associated smpA (97.8%, n
= 177), and the biofilm formation-associated pga genes (95.6%,
n = 173) were harbored by most of the A. baumannii blood
isolates, while the capsule protein mviM (3.9%, n = 7), the
polysaccharide exporter epsA (5.0%, n = 9), lipopolysaccharide
vipA (8.8%, n = 16), and the type IV pili pilA (9.9%, n =
18) genes were occasionally identified. Among the virulence
factors tested, the pga gene was significantly associated with 30-
day death and the adhesion-associated porB had a tendency of
30-day mortality-associated.
A different frequency of each gene by ST was occasionally
identified (Table 2). The psaB gene, formerly the pab2 gene (24),
was identified in all but one (96.6%, 28/29) ST451 isolates.
Antimicrobial Treatment
The majority (95.0%, 172/181) of patients with A. baumannii
BSIs received an empirical antimicrobial therapy with anti-
Acinetobacter drugs and 28.5% (49/172) of those were adequate
(Table 3). The other nine patients received either not-for-
Acinetobacter drugs (n = 7) or none due to refusal of treatment
(n = 2). Among the 132 patients who received an inadequate
empirical therapy, 37.1% (n = 49) of patients were treated
with a definitive antimicrobial therapy within 72 h and 20.4%
(10/49) of those patients met death within 30 days, much
less than that of patients who received a delayed definitive
therapy (57.9%, 48/83).
Risk Factors for 30-Day Mortality
Risk and protective factors associated with the 30-day mortality
in patients with A. baumannii BSIs were searched for
among the variables of P <0.1 through a Cox-regression
univariable analysis. Most of the variables were omitted by
stepwise selection procedure, and each three of risk factors
and protective factors associated with the 30-day mortality
in patients with A. baumannii BSIs were identified through
a Cox-regression multivariable analysis (Table 4): the age of
patients of hazard ratio (95% CI), 1.033 (1.010–1.056); the
SOFA score of 1.133 (1.041–1.233); and the BSI-causative
A. baumannii ST191 of 1.918 (1.073–3.430). Three protective
factors were also identified: the platelet count of 0.996
(0.993–0.999), the BSI-causative A. baumannii ST451 of 0.228
(0.078–0.672), and the definitive therapy within 72 h of
0.255 (0.125–0.519).
DISCUSSION
During the surveillance study period, the overall incidence of A.
baumannii was the third-highest (1.1/10,000 patient-days) BSI-
causative Gram-negative bacteria followed by Escherichia coli
and Klebsiella pneumoniae. Besides, the incidence was strikingly
higher in ICUs (6.6/10,000 patient-days) than in general wards
(0.4/10,000 patient-days) (25). The 30-day mortality rate of
patients with A. baumannii BSIs is pretty varied by study
depending on the subjected patients, and we observed 42.5% of
30-day mortality for entire A. baumannii BSI cases.
Among the variables studied, the old age and the high SOFA
score were identified as the patient-associated risk factors. Those
were reasonable hazardous factors since both factors pronounced
the severity of illness directly or indirectly. A patient-associated
protective factor, platelet counts in peripheral blood reflecting
the patients’ condition also made sense. As well, a treatment-
associated protective factor, a proper definitive therapy within
72 h was comprehensible.
Curiously among the causative-pathogen-associated variables,
the A. baumannii ST191 was a risk factor, while the ST451,
another ICLII member, was a protective factor. A. baumannii
Frontiers in Public Health | www.frontiersin.org 5 August 2019 | Volume 7 | Article 233
Yoon et al. Acinetobacter baumannii Bloodstream Infection
TABLE 2 | Characteristics of the A. baumannii ICLII blood isolates.
Characteristics ICLII P* ST191 P* ST451 P*
n = 153 n = 73 n = 29
Death within 30 days 70 (45.8%) 0.002 44 (60.3%) 0.000 5 (17.2%) 0.013
SOFA score (mean ± SD) 5.9 ± 3.6 0.005 6.2 ± 3.9 0.031 6.4 ± 3.6 0.161
Pulmonary tract of primary site of BSI 61 (39.9%) 0.000 24 (32.9%) 1.000 17 (58.6%) 0.002
Drug resistance
MDR/XDR 151 (98.7%) 0.821 72 (98.6%) 0.003 29 (100%) 0.545
Penicillins NS 146 (95.4%) 0.000 70 (95.9%) 0.000 27 (93.1%) 0.004
3-, 4- gen. cephalosporins NS 151 (98.7%) 0.000 72 (98.6%) 0.000 29 (100%) 0.000
Carbapenems NS 149 (97.4%) 0.000 70 (95.9%) 0.000 29 (100%) 0.000
Aminoglycosides NS 136 (88.9%) 0.000 58 (79.5%) 0.006 29 (100%) 0.000
Fluoroquinolones NS 151 (98.7%) 0.000 72 (98.6%) 0.000 29 (100%) 0.000
Tetracyclines NS 11 (7.2%) 0.354 3 (4.1%) 0.553 6 (20.7%) 0.003
Polymyxin 0 0 0
VIRULENCE FACTORS
Drug resistance
AbGRI1 (Tn6022) 112 (73.2%) 0.000 69 (94.5%) 0.000 5 (17.2%) 0.000
AbaR (Tn6019) 38 (24.8%) 0.164 2 (2.7%) 0.000 24 (82.8%) 0.000
OXA-23 148 (96.7%) 0.000 70 (95.9%) 0.000 28 (96.6%) 0.001
AdeC 32 (20.9%) 0.857 10 (13.7%) 0.110 6 (20.7%) 1.000
Adhesion/Membrane Integrity
Blc 123 (80.4%) 0.002 56 (76.7%) 0.521 22 (75.9%) 1.000
PorB 124 (81%) 0.000 64 (87.7%) 0.001 23 (79.3%) 0.505
SmpA 149 (97.4%) 0.000 72 (98.6%) 0.002 27 (93.1%) 0.747
Biofilm formation
Csu 133 (86.9%) 0.000 62 (84.9%) 0.000 29 (100%) 0.000
Pga 153 (100%) 0.000 73 (100%) 0.000 29 (100%) 0.002
Capsule protein
EpsA 7 (4.6%) 0.742 1 (1.4%) 0.107 3 (10.3%) 0.160
MviM 6 (3.9%) 0.440 0 (0%) 0.099 2 (6.9%) 0.228
Lipopolysaccharide
PsaB 36 (23.5%) 0.000 2 (2.7%) 0.000 28 (96.6%) 0.000
VipA 12 (7.8%) 0.448 7 (9.6%) 0.808 0 (0%) 0.084
Wzx 42 (27.5%) 0.129 17 (23.3%) 0.869 10 (34.5%) 0.172
Carbohydrate metabolism
GntK 153 (100%) 0.000 73 (100%) 0.000 29 (100%) 0.003
Quorum sensing system
LuxR 138 (90.2%) 0.000 65 (89%) 0.175 27 (93.1%) 0.183
Motility and secretion
PilA 14 (9.2%) 0.808 2 (2.7%) 0.015 5 (17.2%) 0.164
Siderophore
BasD 153 (100%) 0.000 73 (100%) 0.000 29 (100%) 0.010
Treatment
Adequate empirical therapy 31 (20.3%) 0.000 16 (21.9%) 0.003 3 (10.3%) 0.002
Definitive therapy within 72 h 46 (30.1%) 0.013 20 (27.4%) 0.624 11 (37.9%) 0.109
*P value is either from Pearson’s X2 test for categorical data or from the t-test for continuous data. The Bonferroni corrected significance level from 33 hypotheses was considered to
be P < 0.0015, and the significant P values are indicated with asterisks.
ICLII, is a well-known multidrug resistant clone (26, 27). The
treatment options for patients infected by the clone are often
limited to the very last resorts, such as carbapenems, tigecycline,
minocycline, and polymyxins. For the infections cause by
multidrug-resistant A. baumannii, the use of combination
antimicrobial therapy is recommended (28) and two thirds
(66.3%, 120/181) of the patients were treated empirically by
antimicrobial combinations. Carbapenem resistance is already
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common in ICLII, and the remaining choices are always
risky because tigecycline (29) and minocycline (30) have a
bacteriostatic activity, which requires a combinational treatment;
colistin has a severe dose-dependent neuro- and nephrotoxicity
(31); and the colistin resistance is easily developed by prior use
of the drug (32). The importance of an adequate antimicrobial
therapy (33), including the proper use of colistin (34), has been
addressed to diminish the 30-day mortality rate caused by A.
TABLE 3 | Antimicrobial regimens for the patients with A. baumannii BSIs.
Regimen No. of cases Proper Improper
Ampicillin 1 0.6% 1 0
Pipercillin/tazobactam 26 14.4% 5 21
comb.w/ciprofloxacin 12 6.6% 1 11
comb.w/tigecycline 2 1.1% 1 1
comb.w/colistin 2 1.1% 2 0
3-, 4- gen. cephalosporins 20 11.0% 5 15
comb.w/ciprofloxacin 8 4.4% 0 8
comb.w/aminoglycosides 2 1.1% 0 2
Carbapenems 55 30.4% 5 50
comb.w/aminoglycosides 2 1.1% 0 2
comb.w/co-trimoxazole 2 1.1% 1 1
comb.w/ciprofloxacin 9 5.0% 1 8
comb.w/colistin 10 5.5% 10 0
Tigecycline 6 3.3% 5 1
comb.w/co-trimoxazole 1 0.6% 1 0
comb.w/fluoroquinolones 2 1.1% 2 0
Colistin 4 2.2% 4 0
Ciprofloxacin 6 3.3% 4 2
Aminoglycosides 1 0.6% 0 1
Co-trimoxazole 1 0.6% 1 0
Not treated* 9 5.0% 0 9
181 49 132
*Patients received drugs not-for-Acinetobacter (n = 7) or none due to refusal of treatment
(n = 2).
baumannii infections. The present results confirmed the notion
through a significant protective effect of the definitive therapy
including colistin. Among ICLII members, ST191 was the most
and both ST784 and ST451 are recently emerging ICLII clones
(27, 32). In this study, ST784 and ST451 were the second and
third most ICLII clones and the clones were evenly recovered
from the six hospitals (Figure 2).
In this study, all but two (98.7%) ICLII blood isolates, one
ST191 and the other ST357, exhibited MDR/XDR. Since drug
resistance is one of the noted hazardous factors obstructing an
adequate antimicrobial therapy (7, 8), similar mortality rates
were presumed for BSIs caused by any STs belonging to the
ICLII. However, a marked difference in 30-day mortality was
observed in the three dominant STs: 60.3% in ST191 BSIs,
45.2% in ST784 BSIs, and 17.2% in ST451 BSIs. Curiously,
the least proportion of patients with ST451 BSIs (10.3%)
were treated by an adequate empirical therapy (Table 2),
indicating that the drug resistance and the relevant adequacy
of treatment were not related to the 30-day mortality rate at
least to BSIs caused by ST191 and ST451. ST451 was more
associated with a primary pulmonary tract infection (58.6%)
than ST191 (32.9%), however the primary site of infection
TABLE 4 | Risk factors associated with the 30-day mortality in patients with A.
baumannii BSI.
Variables VIF* HR [95%CI]† P
Age 1.058 1.033 [1.010–1.056] 0.005
SOFA score 1.335 1.133 [1.041–1.233] 0.004
Platelet 1.290 0.996 [0.993–0.999] 0.016
ST191 1.245 1.918 [1.073–3.430] 0.028
ST451 1.255 0.228 [0.078–0.672] 0.007
Definitive therapy within 72 h 1.094 0.255 [0.125–0.519] <0.001
*VIF, variance inflation factor. The collinearity was diagnosed for the variables including the
multivariate analysis.
†
A Cox-regression multivariate analysis was conducted by the backward method using
the Wald model.
FIGURE 2 | Mortality of BSI patients by causative pathogen. (A) Mortality of patients with BSIs by A. baumannii, (B) comparison of mortality of BSI patients by ICLII
and by non-ICLII A. baumannii, (C) comparison of mortality of BSI patients by ST191, ST451, and other STs belonging to CC91. The Kaplan-Meier plot illustrated
survival in patients with AB-BSI infected with the indicated bacterial clone. Differences between groups were compared by the Log-Rank test of the Mantel-Cox
model, and the P values are presented. ICLII, international clonal lineage II; ST, sequence type.
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was insignificantly associated with a 30-day death (Table 1).
Similarly, ST451 harbored the Tn6019-associated AbaR (82.8%)
more frequently than the Tn6022-associated AbGRI1 (17.2%)
differently from ST191 (2.7 vs. 94.5%), however no difference
was expected since both may harbor the blaOXA−23 gene (12).
The lipooligosaccharide biosynthesis-associated psaB gene was
harbored strikingly more by ST451 than by ST191 (96.6 vs.
2.7%). The psaB gene is a part of the oligosaccharide gene
clusters generating an ordinary side-branch sugar Gal, differing
from the A. baumannii ST191 often carries the gene cluster
producing FucNAc sugar composing the oligosaccharide (24).
Since the lipooligosaccharides of pathogenic bacteria have long
been recognized as a major virulence factor (35), the difference
in oligosaccharides between the two clones is possibly associated
with the 30-day mortality rate and the detailed impact should be
further studied.
This study should be considered with the following caveats
in mind. First, the enrolled cases had a lack of external
validation due to a distinct epidemiology ofA. baumannii clinical
isolates in South Korea in terms of high carbapenem resistance,
mostly conferred by OXA-23. Second, analyses of bacterial
lipooligosaccharides differed by the clones are remained for
further study. However, to the best of our knowledge, this is the
first notification of the counter clinical prognoses of the patients
with a BSI by dominant ICLII clones, drawing an attention to a
further follow-up for the clonal exchange and expansion of ICLII
clones in clinical settings.
This delicate prognosis assessment combined with an
evaluation of the molecular epidemiology for the causative A.
baumannii blood isolates confirmed (i) the predominance
of ICLII in clinical settings, (ii) the hazardousness of
antimicrobial resistance and the importance of an adequate
antimicrobial therapy, and finally, (iii) we highlighted
the differing 30-day mortality rates in patients with BSIs
between causative multidrug-resistant A. baumannii clones
ST191 and ST451 belonging ICLII probably due to the
differing lipooligosaccharides.
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